(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 January 2011 (27.01.2011)

PCT

(10) International Publication Number
WO 2011/009943 A1

(51) International Patent Classification:
C07D 265/30 (2006.01) *A61K 31/5377* (2006.01)
C07D 413/12 (2006.01) *A61K 31/553* (2006.01)
C07D 417/12 (2006.01) *A61P 25/00* (2006.01)
C07D 471/04 (2006.01) *A61P 9/00* (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:
PCT/EP2010/060718

(22) International Filing Date:
23 July 2010 (23.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/228,472	24 July 2009 (24.07.2009)	US
61/258,911	6 November 2009 (06.11.2009)	US
61/363,702	13 July 2010 (13.07.2010)	US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BADIGER, Sangamesh** [IN/IN]; Aurigene Discovery Technologies Limited, 39-40, KIADB Industrial Area, Electronic City Phase II, Hosur Road, Bangalore 560 100 (IN). **CHEBROLU, Murali** [IN/IN]; Aurigene Discovery Technologies Limited, 39-40, KIADB Industrial Area, Electronic City Phase II, Hosur Road, Bangalore 560 100 (IN). **FREDERIKSEN, Mathias** [NO/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **HOLZER, Philipp** [CH/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **HURTH, Konstanze** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **LUEOEND, Rainer Martin** [CH/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **MACHAUER, Rainer** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **MOEBITZ, Henrik** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **NEUMANN, Ulf** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **RAMOS, Rita** [PT/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **RUEEGER, Heinrich** [CH/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **TINTELNOT-BLOMLEY, Marina** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **VEENSTRA, Siem Jacob** [NL/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **VOEGTLE, Markus** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH).

(74) Agent: **VON SPRECHER, Georg**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) Title: OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS



(I)

(57) Abstract: The invention relates to novel heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use as BACE inhibitors for the treatment of Alzheimer and to medicaments comprising them.

WO 2011/009943 A1

Published:

— *with international search report (Art. 21(3))*